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Introduction: Longitudinal assessment of cognitive decline in amnestic mild cognitive impairment (aMCI) and
Alzheimer’s disease (AD) often involves the use of both informant-based and objective cognitive assessments. As
efforts have focused on identifying individuals in pre-clinical stages, instruments that are sensitive to subtle cognitive
changes are needed. The Alzheimer’s Questionnaire (AQ) has demonstrated high sensitivity and specificity in identifying
aMCI and AD; however its ability to measure longitudinal change has not been assessed. The aims of this study are to
assess the sensitivity to change of the AQ and to determine whether the AQ predicts change in global cognition and
function in cognitively normal (CN), aMCI, and AD subjects.
Methods: Data from 202 individuals participating in a brain and body donation program were utilized for this study
(101 CN, 62 aMCI, 39 AD). AD and aMCI individuals were matched on age, education, and gender to CN individuals.
Sensitivity to change of the AQ was assessed in addition to the AQ’s ability to predict change in global cognition and
function. The Mini Mental State Exam (MMSE) and Functional Activities Questionnaire (FAQ) were used as gold
standard comparisons of cognition and function. Sample size calculations for a 25% treatment effect were also
carried out for all three groups.
Results: The AQ demonstrated small sensitivity to change in the aMCI and CN groups (d = 0.33, d = 0.23, respectively)
and moderate sensitivity to change in the AD group (d = 0.43). The AQ was associated with increases in the Clinical
Dementia Rating Global Score (OR = 1.20 (1.09, 1.32), P <0.001). Sample size calculations found that the AQ would require
substantially fewer subjects than the MMSE given a 25% treatment effect.
Conclusions: Although the AQ demonstrated small sensitivity to change in aMCI and CN individuals in terms of effect
size, the AQ may be superior to objective cognitive tests in terms of required sample size for a clinical trial. As clinicians
and researchers continue to identify and treat individuals in earlier stages of AD, there is a need for instruments that are
sensitive to cognitive changes in these earlier stages.Introduction
Longitudinal assessment of cognitive decline in amnestic
mild cognitive impairment (aMCI) and Alzheimer’s
disease (AD) often involves the use of both informant-
based and patient-based assessments to measure the
degree of change in cognition and function [1,2]. In both
clinical and research settings, the two methods are often
used in conjunction in order to glean a more accurate
picture of an individual’s current cognitive status relative
to baseline or other prior time points. A major issue that* Correspondence: michael.ahmadi@bannerhealth.com
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article, unless otherwise stated.both clinicians and researchers grapple with is the
degree to which a particular instrument is sensitive to
change over time. For clinicians, determining the signifi-
cance of change from one time to the next has implica-
tions for decisions regarding treatment and resource use
(that is, assisted living, in-home care, and so on.). Clini-
cians may also benefit from instruments that are sensitive
to change over time in order to satisfy the Affordable
Care Act’s cognitive screening requirement for Medicare
recipients. For researchers and clinical trialists, the issue
of sensitivity to change for a particular instrument has
significant ramifications for whether or not a meaningful
treatment effect will be detected between placebo and
treatment groups.Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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the AD disease process has prompted researchers to
begin conducting studies with individuals who are classi-
fied as having pre-symptomatic AD. Although no formal
diagnostic criteria currently exist for this classification, it
is used to classify individuals whose biological markers
are consistent with the pathological presence of AD, but
who are cognitively normal and are considered to be at
risk for eventually developing clinical AD. An interesting
study by Riley et al. [3] compared cognitively normal
individuals who, at autopsy, met National Institute on
Aging (NIA)-Reagan criteria for no- and low-likelihood
of AD with cognitively normal individuals who met cri-
teria for intermediate- and high-likelihood of AD. This
study found that the intermediate- and high-likelihood
groups had a steeper rate of decline on several cognitive
measures across several domains, although all individ-
uals in the study were within normal limits on cognitive
testing. Riley et al. [3] suggest that rates of longitudinal
cognitive decline may be informative in identifying indi-
viduals with pre-symptomatic AD, even when cognitive
testing falls within normal limits. Gavett et al. [4] found
that informant-reported cognitive symptoms on the
Informant Questionnaire on Cognitive Decline in the
Elderly (IQCODE) correlated well with longitudinal neuro-
psychological performance and that informant-reported
changes in cognition were a robust predictor of cognitive
decline in a high-functioning, cognitively normal group.
Both of these studies demonstrate that cognitive decline
in cognitively normal individuals can be reliably detected
and may be used to predict subsequent development of
clinical AD.
The Alzheimer’s Questionnaire (AQ) was originally in-
troduced in 2010 [5] and has been validated as an accur-
ate informant-based measure of cognition and function
for both aMCI and AD [5-7]. The AQ also correlates
well with established measures of cognition and global
function [8]. Although the AQ has demonstrated its
validity in cross-sectional studies, its ability to accurately
measure change in cognition over time has not been
assessed. Instruments such as the Mini Mental State Exam
(MMSE) [9] and the Functional Activities Questionnaire
(FAQ) [10] are commonly used to assess changes in cogni-
tion and function in aMCI and AD. Clark et al. [11] report
that although the MMSE may be sufficient to use as a
screening instrument for cognitive impairment, its utility
as an instrument to assess change over time accurately is
limited by high measurement error and high variability
of annual change between individuals. A recent study
by Costa et al. [12] found that the Montreal Cognitive
Assessment (MoCA) yielded small sensitivity to change
in prodromal AD and moderate sensitivity to change in
mild AD. Recent studies suggest that the FAQ is a sig-
nificant predictor of conversion to AD from aMCI [13]and has also been associated with longitudinal decreases
in glucose metabolism associated with aMCI and AD
[14]. Rizk-Jackson et al. [15] found that the FAQ was able
to detect functional decline in cognitively normal individ-
uals prior to the presence of impairment on objective
cognitive tests.
The first aim of this study was to assess the sensitivity
to change of the AQ through the use of effect size and
sample size calculations for a hypothetical placebo-
controlled clinical trial. For comparison, the MMSE and
FAQ were also used in order to gauge the AQ’s perform-
ance against instruments that have been more widely
used. The second aim of the study was to determine
how well one-year change in AQ total score predicts
global change as measured by the Functional Assessment
Staging Test (FAST) [16], Global Deterioration Scale




Data from the two most recent annual visits for 202
individuals participating in a brain and body donation
program [19] were utilized for this study. Participants
in this program were recruited predominantly from the
northwest region of the Phoenix, Arizona metropolitan
area. Approval for the brain and body donation pro-
gram was granted by the Banner Health Institutional
Review Board and informed consent was obtained from
all individuals prior to enrolling in the program. The
sample for this study ranged in age from 57 to 97 years
with a mean of 81.70 ± 7.25 and had a mean education
level of 14.74 ± 2.54 years and included 95 women and
107 men.
Of the 202 individuals, 101 were classified as cogni-
tively normal (CN), 62 were classified as amnestic mild
cognitive impairment (aMCI), and 39 were classified as
Alzheimer’s disease (AD) at the first visit. Each aMCI
and AD individual was matched on age, education,
and gender to a CN individual, without replacement.
When an exact match could not be found, a tolerance
of ± 2 years was used for age and education in order to
obtain an appropriate match. Both single and multiple
domain aMCI cases were categorized as aMCI and both
possible and probable AD were categorized as AD. The
AD cases met National Institute of Neurological and
Communicable Disorders and Stroke – Alzheimer’s
Disease and Related Disorders Association (NINCDS-
ADRDA) criteria [20] for a clinical diagnosis of probable or
possible Alzheimer’s disease. aMCI cases were diagnosed
as such based on Petersen criteria [21]. The CN cases were
defined as having no limitations of activities of daily living
by informant report and were within normal limits on
neuropsychological testing.
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iatrist and neuropsychologist was used to determine the
clinical status of each individual. Consensus diagnoses were
made based on neuropsychological testing results, neuro-
logical and physical exam, and interviews with an inform-
ant that assessed global cognitive status, functional status,
and mood and behavioral status.
Instruments
AQ [5,6] – A 21-item, informant-based dementia assess-
ment designed for ease of use in a primary care setting.
AQ items are divided into five domains including Memory,
Orientation, Functional Ability, Visuospatial Ability, and
Language. Items are posed in a yes/no format with the
sum of ‘yes’ items equaling the total AQ score (0-27).
Six items known to be predictive of a clinical AD diagnosis
are weighted more heavily in the total score by each being
worth two points rather than one.
FAQ [11] – An informant-based measure of instru-
mental activities of daily living (IADLs) which scores 10
items on a 0 to 3 scale, with higher scores corresponding
to greater impairment.
MMSE [9] – A brief, 30-item cognitive screening
instrument that includes items on Orientation, Memory,
Attention, Language and Visuospatial functions.
FAST [16] – A dementia staging instrument that classi-
fies individuals as Normal Aging, Possible Mild Cognitive
Impairment, Mild Cognitive Impairment, Mild Dementia,
Moderate Dementia, Moderately Severe Dementia and
Severe Dementia using a 1 to 7 scale where higher ratings
indicate greater severity.
GDS [17] – A dementia staging instrument divided
into seven different stages with increasing impairment
corresponding with higher stages (No Cognitive Decline,
Age-Associated Memory Impairment, Mild Cognitive
Impairment, Mild Dementia, Moderate Dementia, Moder-
ately Severe Dementia, Severe Dementia).
CDR [18] –A semi-structured, informant-based clinical
staging instrument that characterizes six domains of cogni-
tive and functional performance: Memory, Orientation,
Judgment and Problem Solving, Community Affairs, Home
and Hobbies, and Personal Care. The CDR provides a glo-
bal score which is a composite score based on an algorithm
that gives different weights to the scores for each of the do-
mains. The global score (GS) is used to grade the severity
of dementia and is measured using 0, 0.5, 1, 2, and 3 to de-
note no impairment, very mild dementia, mild dementia,
moderate dementia, and severe dementia, respectively.
Statistical analysis
The Shapiro-Wilk test was performed on the data to de-
termine the normality of distribution for the continuous
variables. Non-parametric tests for group comparisons
and correlations were used, as the data for all continuousvariables were not normally distributed. The Kruskall-
Wallis test was used to verify that the three groups were
not significantly different in terms of age and education.
Chi-square analysis was used to examine the distribution
of men and women among the three groups.
The analyses investigating the sensitivity to change uti-
lized a method similar to that of Costa et al. [11]. Mid-
del and von Sonderen [22,23] described these methods
and their rationale in detail. The sensitivity to change
assessment was completed through the calculation of an
effect size (ES) to quantify the magnitude of change.
Since this study used a correlated design, the pooled
standard deviation was used to calculate the ES which
was taken from the individual standard deviation values
for Year 1 and Year 2 for each measure (pooled standard
deviation = √(((Year 1 sd)2 + (Year 2 sd)2)/2); (ES =mean
change score/pooled standard deviation)). The final ef-
fect size measure, d, included a correction for reliability
(d = ES/√2(1-r)) where r is the correlation between
the scores at Year 1 and Year 2. The interpretation
for d utilized the following scheme proposed by Cohen
[24]: <0.20 = trivial change; 0.20 to 0.50 = small change;
0.50 to 0.80 =moderate change; ≥0.80 = large change.
In order to provide a more practical interpretation of
the sensitivity to change, a series of sample size calcula-
tions were carried out to show how many individuals
would be needed for a clinical trial using a particular
measure as its outcome. The sample size calculations as-
sumed a 25% treatment effect on the mean change score
for each measure at 80% power with a two-tailed signifi-
cance level of 0.05 for a randomized clinical trial with a
treatment arm and a placebo arm. These parameters
were used as they have been utilized by several previous
studies [25] and have also been used to estimate sample
sizes for pre-dementia trials using data from the Alzhei-
mer’s Disease Neuroimaging Initiative [26]. Sample size
calculations were carried out using G*Power 3 [27]. The
reported sample sizes are the number per arm. For each
of the clinical groups, varying trial lengths were used in the
sample size calculations: AD = two years, MCI = three
years, CN = five years.
To further examine the ability of each instrument to
detect clinically significant change, a reliable change
index (RCI) was calculated for each instrument. For this
study, two different RCI methods were utilized as the
AQ and FAQ are informant-based assessments and the
MMSE is an objective performance-based assessment.
For the AQ and FAQ, RCI calculations that corrected
for inter-test reliability were used [28] while the MMSE
RCI calculation utilized a method that corrects for both
inter-test reliability and practice effects [29]. The most
common convention for interpreting RCI scores is that
scores that are ≥ ± 1.645 are interpreted as demonstrat-
ing clinically significant change [30]. This was used to
Malek-Ahmadi et al. Alzheimer's Research & Therapy  (2015) 7:1 Page 4 of 9obtain 90% confidence intervals for estimates of clinic-
ally significant change for each instrument from Year 1
to Year 2. In this study, we report the percent of
individuals who demonstrated annual score changes
outside the range of the 90% confidence interval for each
instrument.
An additional set of analyses were carried out to deter-
mine the extent to which the mean change scores of the
AQ, FAQ and MMSE predicted global change as mea-
sured by increases in FAST, GDS and CDR-GS values.
The CN, AD and aMCI groups were analyzed separately.
An analysis with the entire sample was also carried out.
All individuals were dichotomized based on whether
their individual FAST, GDS and CDR-GS values in-
creased from Year 1 to Year 2 (1 = increase, 0 = no
increase) as increases on these scales represent clinically
meaningful changes in disease severity. Logistic regres-
sion analyses were used to assess the predictive value of
the AQ, FAQ and MMSE change scores on increases in
FAST, GDS or CDR-GS. A False Discovery Rate (FDR)
significance level of 0.006 was used to correct for
multiple comparisons within each of the groups.
Spearman correlation analyses were carried out to
assess the linear associations between AQ, FAQ and
MMSE scores with the FAST, GDS and CDR-GS for
Year 1 and Year 2 separately. Spearman correlation was
also used to assess the associations between the change
scores on the AQ, FAQ, MMSE and MoCA. The corre-
lations used as the measures of test-retest reliability are
also Spearman values. Statistical analyses were carried
out using Systat 12.0 (Systat, Inc., San Jose, CA, USA).
Results
Demographic characteristics of the entire study sample
and each clinical group are shown in Table 1. The three
clinical groups did not differ in terms of age or years of
education and there was no significant difference in gen-
der composition among the three groups.
The results from the sensitivity to change analysis are
shown in Table 2. In the aMCI group the AQ, FAQ and
MMSE all demonstrated small sensitivity to change in
terms of their respective d values (0.33, 0.35, 0.24). How-
ever, both the AQ and FAQ yielded required sample
sizes that were less than half of the sample size required
by the MMSE.Table 1 Demographic characteristics
Characteristic CN MCI
Number 101 62
Age 81.76 ± 7.23 81.57 ± 7.59
Education 14.69 ± 2.50 15.18 ± 2.56
Gender (M/F) 53/48 33/29
Mean ± standard deviation. AD, Alzheimer’s disease; CN, cognitively normal; MCI, mIn the AD group, the AQ demonstrated small sensitiv-
ity to change (d = 0.43),; however, the FAQ showed large
sensitivity to change (d = 0.84) and the MMSE demon-
strated moderate sensitivity to change (d = 0.52). In
terms of required sample size the FAQ yielded the
lowest value (n = 119) while the AQ yielded a value that
was substantially higher (n = 232). This result may be ex-
plained by the reliability values for each instrument as
the FAQ had a higher reliability value (r = 0.81) than the
AQ (r = 0.64). The MMSE yielded a required sample size
that was between that of the AQ and FAQ (n = 157).
In the CN group all three measures demonstrated trivial
sensitivity to change. However, sample size calculations
demonstrated that the MMSE would require substantially
more subjects than both the AQ and FAQ.
Results from the RCI score calculations are shown in
Table 3. For the aMCI group, the AQ yielded a higher
percentage of individuals demonstrating clinically signifi-
cant change when compared to the FAQ and MMSE.
For the AD group, the AQ yielded a higher percentage
of individuals demonstrating clinically significant change
when compared to the FAQ, but demonstrated an
equivalent percentage compared to the MMSE. Table 4
shows the results of the predictive ability of AQ, FAQ
and MMSE mean change scores on increases in FAST,
GDS and CDR-GS values. Within each of the clinical
groups, no statistically significant effects were found after
adjusting for multiple comparisons. When all three
groups were pooled together, the AQ and FAQ dem-
onstrated small, but significant associations with CDR-
GS increases (AQ (odds ratio (OR) = 1.20 (1.09, 1.32),
P <0.001); FAQ (OR = 1.21 (1.11, 1.33), P <0.001)). The
pooled analysis also yielded a small, but significant associ-
ation for FAQ mean change and GDS increase (OR = 1.16
(1.06, 1.26), P = 0.001).
Correlation values for first and second year scores for
each instrument are shown in Tables 5 and 6. The AQ
and FAQ correlated strongly with FAST, GDS and CDR-
GS values in both years while the MMSE correlated
moderately with FAST, GDS and CDR-GS values in Year
1. In Year 2, the MMSE correlated moderately with the
FAST and GDS, but demonstrated a strong correlation
with the CDR-GS.
The mean change score for the AQ correlated weakly
with the mean FAQ change score (r = 0.22, P = 0.002)AD Total P-value
39 202 -----
81.82 ± 6.92 81.71 ± 7.25 0.99
14.15 ± 2.55 14.74 ± 2.54 0.12
21/18 107/95 0.99
ild cognitive impairment; M/F, male/female.
Table 2 Sensitivity to change comparison for the AQ, FAQ, and MMSE in amnestic mild cognitive impairment,
Alzheimer’s disease, and cognitively normal cases
Group Instrument Mean change SD of mean change 95% CI of mean change Pooled SD ES Reliability d Required sample
sizea
aMCI
AQ 1.66 4.96 (0.40, 2.92) 6.10 0.27 0.65 0.33 251
FAQ 2.05 5.79 (0.54, 3.56) 3.29 0.30 0.63 0.35 224
MMSE -0.55 2.54 (-1.19, 0.10) 2.47 0.22 0.56 0.24 597
AD
AQ 2.49 4.77 (0.94, 4.03) 6.75 0.37 0.64 0.43 232
FAQ 3.59 4.91 (2.00, 5.18) 5.36 0.52 0.81 0.84 119
MMSE -2.13 3.35 (-3.23, -1.03) 6.34 0.34 0.79 0.52 157
CN
AQ 0.47 2.73 (-0.07, 1.00) 3.37 0.14 0.69 0.18 340
FAQ 0.33 1.80 (-0.03, 0.69) 3.29 0.11 0.73 0.15 300
MMSE 0.05 1.71 (-0.29, 0.39) 2.47 0.02 0.41 0.02 660
aNumber of subjects per arm based on a 25% treatment effect of the mean change at 80% power with a two-tailed significance level of 0.05; sample size estimates are
based on a two-year study for AD, a three-year study for aMCI, and five-year study for CN; for AQ and FAQ positive mean change scores represent increased impairment
over time and negative mean change scores for MMSE also represent increased impairment over time. Effect size values are reported in absolute values and represent
the magnitude of the difference for Year 2 scores subtracted from Year 1 scores. AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; AQ, Alzheimer’s
Questionnaire; 95% CI, 95% confidence interval; CN, cognitively normal; d, effect size corrected for reliability; ES; effect size using pooled standard deviation;
FAQ, Functional Activities Questionnaire; MMSE, Mini Mental State Exam; SD, standard deviation.
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correlation with the AQ mean change score (r = -0.02,
P = 0.83).
Discussion
Within the aMCI and AD groups the AQ demonstrated
small sensitivity to change while its sensitivity to change
in the CN group was trivial. In aMCI individuals the
AQ, FAQ and MMSE all demonstrated small sensitivity
to change. In the AD group, the MMSE and FAQ dem-
onstrated greater sensitivity to change relative to the
AQ. The AQ was also significantly associated with global
change as measured by CDR-GS increase and correlated
strongly with other established measures of global cogni-
tion and function. Although the effect sizes reported in
this study are relatively small, they are consistent with
the notion that cognitive changes associated with aMCI
and AD are often subtle and difficult to detect from a
psychometric standpoint. This point is a major challenge
for researchers and clinical trialists as the variability of
cognitive tests is often numerically similar to the rate ofTable 3 Reliable change index results based on data from cog
Instrument Reliability SEm SEdiff
AQ 0.69 0.27 2.66
FAQ 0.73 0.18 2.24
MMSE 0.41 0.17 1.73
AD, Alzheimer’s disease; AQ, Alzheimer’s Questionnaire; CI, confidence interval; FAQ
reliable change index; SEdiff, standard error of the difference; SEm, standard error ofchange [31]. Informant-based instruments that assess
functional ability are also prone to high degrees of vari-
ability due to varying pre-morbid levels of function and
gender differences in the degree of participation in many
of the functional activities that are assessed [31]. The re-
sult is that when objective cognitive tests and informant-
based instruments are used as endpoints in clinical trials
the inherent variability of these measures often makes it
difficult to detect true differences between placebo and
treatment groups. However, others have suggested that
lack of decline in placebo groups [32] and disease sever-
ity at baseline [31] can also significantly impact a trial’s
ability to detect a significant treatment effect. The degree
to which a particular cognitive or functional measure is re-
sponsive to changes in disease status is extremely import-
ant, particularly in pre-symptomatic and aMCI populations
where cognitive decline is slower and more subtle [33].
The sample size calculations in the aMCI group dem-
onstrate that the AQ is superior to the MMSE in terms
of sensitivity to change; however, the AQ required a larger
sample size than the FAQ. The sample size calculationsnitively normal individuals
90% CI for RCI Percent outside of 90% CI
±4.37 aMCI = 24%; AD = 16%
±3.67 aMCI = 17%; AD = 12%
±2.84 aMCI = 17%; AD = 17%
, Functional Activities Questionnaire; MMSE, Mimi Mental State Exam; RCI,
measurement.
Table 4 AQ, FAQ, and MMSE mean change as predictors of global change in mild cognitive impairment, Alzheimer’s
disease, cognitively normal cases, and all groups combined
Group Instrument FAST increase GDS increase CDR Global score increase
aMCI
AQ 1.07 (0.96, 1.20); P = 0.23 1.09 (0.97, 1.22); P = 0.15 1.09 (0.97, 1.24); P = 0.16
FAQ 1.07 (0.96, 1.19); P = 0.25 0.97 (0.87, 1.08); P = 0.52 1.08 (0.96, 1.22); P = 0.22
MMSE 1.02 (0.83, 1.26); P = 0.83 0.81 (0.64, 1.02); P = 0.07 0.91 (0.72, 1.15); P = 0.43
AD
AQ 1.17 (0.97, 1.29); P = 0.14 1.26 (1.05, 1.52); P = 0.01 1.16 (1.00, 1.35); P = 0.06
FAQ 1.09 (0.95, 1.24); P = 0.22 1.17 (1.00, 1.38); P = 0.05 1.12 (0.97, 1.29); P = 0.12
MMSE 0.93 (0.77, 1.14); P = 0.50 0.97 (0.79, 1.19); P = 0.77 0.91 (0.74, 1.11); P = 0.35
CN
AQ 1.09 (0.93, 1.28); P = 0.29 1.04 (0.88, 1.23); P = 0.67 1.26 (1.00, 1.59); P = 0.05
FAQ 0.91 (0.68, 1.22); P = 0.52 1.02 (0.77, 1.34); P = 0.92 1.61 (1.10, 2.36); P = 0.02
MMSE 0.88 (0.66, 1.17); P = 0.38 0.94 (0.70, 1.25); P = 0.66 0.72 (0.35, 1.49); P = 0.37
All Groups Combined
AQ 1.11 (1.03, 1.20); P = 0.008 1.08 (1.00, 1.16); P = 0.05 1.20 (1.09, 1.32); P <0.001
FAQ 1.09 (1.01, 1.18); P = 0.03 1.16 (1.06, 1.26); P = 0.001 1.21 (1.11, 1.33); P <0.001
MMSE 0.91 (0.81, 1.03); P = 0.15 0.84 (0.74, 0.95); P = 0.006 0.91 (0.74, 1.11); P = 0.35
Odds ratio (95% confidence interval); P-value; FDR significance level = 0.006; odds ratios indicate the association for a 1-point increase in AQ, FAQ, and MMSE
change scores with FAST, GDS and CDR-GS score increase as the outcome. AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; AQ, Alzheimer’s
Questionnaire; CI, confidence interval; CDR, Clinical Dementia Rating; CN, cognitively normal; FAQ, Functional Activities Questionnaire; FAST, Functional Assessment
Staging Test; GDS, Global Deterioration Score; MMSE, Mini Mental State Exam; MoCA, Montreal Cognitive Assessment.
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and AD studies that have been problematic. The first issue
involves whether or not objective cognitive tests and
informant-based instruments are sensitive enough to
detect changes, particularly in earlier stages of aMCI and
AD. Based on the results from the MMSE, our results sug-
gest that the AQ may be superior to objective cognitive
measures in detecting longitudinal change when com-
pared on sample sizes required to detect a treatment
effect. Although informant-based and objective cogni-
tive assessments are often used in conjunction to as-
sess drug efficacy, these results suggest that the MMSE is
less sensitive to change over time than informant-based
instruments.
Another issue these results highlight is that of instru-
ment reliability as it relates to the required sample sizeTable 5 Correlation values for AQ, FAQ, MMSE, FAST, GDS
and CDR Global Score for Year 1
Instrument FAST Year 1 GDS Year 1 CDR-GS Year 1
AQ Year 1 0.84 0.78 0.74
FAQ Year 1 0.83 0.77 0.75
MMSE Year 1 -0.59 -0.64 -0.65
P <0.001 for all correlations. AQ, Alzheimer’s Questionnaire; CDR, Clinical
Dementia Rating; FAQ, Functional Activities Questionnaire; FAST, Functional
Assessment Staging Test; GDS, Global Deterioration Scale; MMSE, Mini Mental
State Exam.needed to detect a treatment effect. There is a direct re-
lationship between instrument reliability and sensitivity
to change as instruments that are prone to higher vari-
ability between assessments may not detect significant
longitudinal change as accurately as instruments with
lower between-assessment variability. This imprecision
ultimately leads to larger sample size requirements for
clinical trials. Knopman and Caselli [34] point out that
between-assessment variability is an inherent challenge
when using patient-based objective cognitive tests to as-
sess change, and longitudinal differences may be related
to non-pathological factors, such as chance and regres-
sion toward the mean. Practice effects due to repeat
administration of cognitive tests within relatively short
periods of time also pose a significant threat to the
ability to detect change associated with progression ofTable 6 Correlation values for AQ, FAQ, MMSE, FAST, GDS
and CDR Global Score for Year 2
Instrument FAST Year 2 GDS Year 2 CDR-GS Year 2
AQ Year 2 0.80 0.80 0.75
FAQ Year 2 0.81 0.81 0.83
MMSE Year 2 -0.67 -0.72 -0.69
P <0.001 for all correlations. AQ, Alzheimer’s Questionnaire; CDR, Clinical
Dementia Rating; FAQ, Functional Activities Questionnaire; FAST, Functional
Assessment Staging Test; GDS, Global Deterioration Scale; MMSE, Mini Mental
State Exam.
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objective cognitive tests are inherently insensitive to cog-
nitive changes [36] and that variability between exam-
iners using these instruments [37] is also a detrimental
factor that prevents treatment effects from being ob-
served. Although informant-based measures are more
robust to some of these challenges than objective cogni-
tive tests, they are still prone to some degree of meas-
urement error, particularly in the area of inter-rater
reliability [38].
In this study, the issue of reliability and its relationship
to effect size was demonstrated in the AD group where
the AQ yielded moderate sensitivity to change and the
FAQ yielded large sensitivity to change. In this case, the
effect size (corrected for reliability) for the FAQ was
almost twice as large as that of the AQ. Some of this
difference may be attributable to the higher reliability
value of the FAQ which underscores the importance of
not only an instrument’s psychometric ability to detect
change, but also the ability of the examiner to admin-
ister the instrument in a way that can detect meaning-
ful change. The importance of inter-rater reliability is
highlighted by Kobak [39] who points out that reduc-
tions in inter-rater reliability, as measured by intra-class
correlation, can result in significantly larger required sam-
ple sizes for clinical trials which stems from the increased
measurement variability that reduces statistical power.
This issue is also highlighted by Cummings et al. [40] who
report that insufficient training and monitoring of exam-
iners may lead to increased measurement variability which
decreases the chance of detecting significant treatment
effects. Connor and Sabbagh [41] also note that increases
in measurement error may lead to decreases in instrument
reliability, which results in a decreased ability to detect
treatment effects.
The divergent sample size calculations for the AQ and
FAQ may also be due to some of the inherent psycho-
metric properties of each instrument. The FAQ captures
not only the presence of impaired functioning, but also
severity where the AQ only captures the presence of
reported impairment in cognition and function. Thus,
the inclusion of severity of impairment on the FAQ may
account for the smaller required sample size calculation
as a result of increased statistical power.
The results from the RCI calculations showed that the
AQ identified clinically significant change in a larger
percentage of individuals than did the FAQ and MMSE
for aMCI individuals. The advantage that RCI scores
provide is the ability to assess intra-individual change,
which has been shown to have good predictive value in
terms of cognitive decline [42]. The use of RCI scores in
this context may provide a novel and more informative
way to determine endpoints for aMCI and AD clinical
trials. Since the majority of clinical trials for aMCI andAD rely on methods and analyses that simply assess
group differences (for example, drug versus placebo) on
a particular measure (for example, Alzheimer’s Disease
Assessment Scale – cognition (ADAS-Cog)), it might be
possible for drug efficacy to be assessed based on the per-
cent of individuals showing clinically significant change
on a measure, rather than just demonstrating a certain
amount of change (for example, 25%) on an outcome
measure.
One drawback to the current study is the relatively
small sample size. Given that clinical trials often enroll
hundreds of individuals, replication of these findings in a
larger sample is needed in order to strengthen the argu-
ment for the AQ’s ability to detect longitudinal change.
Autopsy confirmation of the clinical status for each indi-
vidual would lend further support to the AQ’s ability to
detect longitudinal change. Although the individuals par-
ticipating in this study have agreed to an autopsy, many
of them were still living at the time of the analysis so
neuropathological confirmation of their clinical status
was not available.Conclusions
The results of this study indicate that the AQ demon-
strated small sensitivity to longitudinal cognitive changes
associated with aMCI and AD. The AQ’s sensitivity to
change in aMCI was comparable to the FAQ while both
instruments outperformed the MMSE in terms of effect
size and required sample size. The AQ was also signifi-
cantly associated with longitudinal decreases in global
cognition and function and was able to identify a greater
proportion of aMCI individuals with clinically significant
change when compared to other established measures.
As clinicians and researchers continue to identify and
treat individuals in earlier stages of AD, there is a need
to utilize instruments that are sensitive to subtle cogni-
tive changes over time. Although the AQ’s sensitivity
to change was small, it is possible that its sensitivity
to change may be enhanced when used in conjunction
with sensitive objective cognitive tests and validated bio-
markers of disease progression. In addition, the recent
changes in mandatory screening measures for Medicare
recipients as part of the Affordable Care Act may pro-
vide the opportunity for the AQ to be used by clinicians
in order to satisfy the requirement for cognitive screen-
ing and might be helpful in detecting change over time
in clinical settings.
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